Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry

Table 5 Lipid profile of children on lipid-lowering treatment

Parameter	Children
	Statin ± Ezetimibe (n = 57)
	Pre-treatment	Post-treatment
Total cholesterol, mg/dL (mmol/L)	322 ± 81 (8.3 ± 2.1)	233 ± 133^§ (6.0 ± 3.4)^§
Triglycerides, mg/dL (mmol/L)	77 (53–105) [0.9 (0.6–1.2)]	66 (53–89) [0.7 (0.6–1.0)]
HDL-C, mg/dL (mmol/L)	54 ± 14 (1.4 ± 0.4)	52 ± 12 (1.3 ± 0.3)
non-HDL-C, mg/dL (mmol/L)	268 ± 81 (6.9 ± 2.1)	180 ± 136^§ (4.7 ± 35) ^§
LDL-C_F, mg/dL (mmol/L)	251 ± 79 (6.5 ± 2.0)	148 ± 58^§ (3.8 ± 1.5) ^§
LDL-C_M/H, mg/dL (mmol/L)	248 ± 79 (6.4 ± 2.0)	146 ± 57^§ (3.8 ± 1.5)^§
^aLDL-C_Lp(a)corM/H, mg/dL (mmol/L)	253 ± 88 (6.5 ± 2.3)	125 ± 54^†,§,§§ (3.2 ± 1.4)^§,§§
^aLp(a), mg/dL (nmol/L)	21 (6–86) [42.0 (9.3–183.7)]	21 (9–61) [42.0 (15.8–129.2)]

Data are presented as mean ± standard deviation or median (interquartile range) for parametric and non-parametric variables, respectively
HDL-C High-density lipoprotein cholesterol, LDL-C_F Low-density lipoprotein cholesterol as calculated by the Friedewald formula, LDL-C_M/H Low-density lipoprotein cholesterol as calculated by the Marin/Hopkins formula, LDL-C_Lp(a)corM/H Corrected for Lp(a) levels low-density lipoprotein cholesterol as calculated by the Marin/Hopkins formula, PCKS9i Proprotein convertase subtilisin/kexin type 9 inhibitor, Lp(a) was converted using the formula: Lp(a) nmol/L = 2.18 × Lp(a) mg/dL − 3.83
^†: P < 0.001 vs LDL-C_F, ^§P < 0.001 vs pre-treatment, ^§§P < 0.001 for the comparison of LDL-C change compared with the change of LDL-C_F and LDL-C_M/H
^a: Data available for 40 patients

ISSN: 1476-511X